Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment ...
Pfizer is navigating declining COVID-19 product sales and looming patent expirations by leaning on new drug launches, acquisitions, and a robust pipeline to sustain its 6.4% forward dividend yield.
Key opportunities include capitalizing on rising screen time, increased demand for preservative-free & advanced formulations, ...
Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results